In this insightful video, Dr. Gunjan Desai, a Gastrointestinal, Liver, and Pancreatic Surgeon at Lilavati Hospital, Mumbai, delves into the groundbreaking EMERALD trials for liver cancer treatment, with a specific focus on hepatocellular carcinoma (HCC). This comprehensive discussion is tailored for medical professionals, researchers, and anyone keen to understand the latest advancements in HCC management.
Dr. Desai explains the sub-classification of BCLC intermediate-stage HCC as per the within up to 7 criteria for TACE suitability, emphasizing its clinical significance in determining tailored treatment strategies. He highlights how the complexities of this stage demand innovative and precise therapeutic approaches.
The video then transitions into a detailed overview of the EMERALD-1 trial, a pivotal study exploring the use of Durvalumab combined with Bevacizumab as a treatment with TACE for patients with intermediate stage HCC. Dr. Desai discusses the trial's design, patient selection criteria, primary and secondary endpoints, and the significance of this novel combination therapy in preventing progression and improving overall survival rates.
Following this, Dr. Desai provides insights into the EMERALD-2 trial, which investigates the efficacy of Durvalumab combined with Bevacizumab as an adjuvant therapy after curative resection for high-risk HCC. He sheds light on the implications of this combination therapy in redefining the therapeutic landscape for these patients.
The discussion concludes with briefly mentioning the EMERALD-3 trial, which focuses on Durvalumab combined with Tremelimumab and lenvatinib in intermediate stage HCC stages with TACE.
Dr. Desai ties all these elements together, offering his expert perspective on how the EMERALD trials collectively pave the way for a new era of personalized medicine in HCC treatment.
FACEBOOK: https://bit.ly/3qaO53R
TWITTER: https://bit.ly/3legZw7
INSTAGRAM: https://bit.ly/33mAJaK
E-MAIL ID: learnwithedusurg@gmail.com
Freedom of expression, positivity, and meditation